Systemic Therapies for Acne

Acneiform Eruptions in Dermatology: A Differential Diagnosis

Volumn , Issue , 2014, Pages 27-34

  Garshick, Marisa Kardos ^a   Kimball, Alexa ^a   Drake, Lynn ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84956791012     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-8344-1_4     Document Type: Chapter

References (53)

1. Del Rosso JQ, Kim G. Optimizing use of oral antibiotics in acne vulgaris. Dermatol Clin. 2009;27:33–42.
2. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49:S1–37.
3. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003;49(3):S200–10.
4. Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56:651–63.
5. Rafi ei R, Yaghoobi R. Azithromycin versus tetracycline in the treatment of acne vulgaris. J Dermatolog Treat. 2006;17:217–21.
6. Kus S, Yucelten D, Aytug A. Comparison of effi cacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. Clin Exp Dermatol. 2005;30:215–20.
7. Antonio JR, Pegas JR, Cestari T, Do Nascimento LV. Azithromycin pulses in the treatment of infl ammatory and pustular acne: effi cacy, tolerability and safety. J Dermatolog Treat. 2008; 19:210–5.
8. Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other infl ammatory skin disorders: focus on antibiotic resistance. Cutis. 2007;79:9–25.
9. Eady EA, Cove JH, Holland KT, Cunliffe WJ. Superior antibacterial action and reduced incidence of bacterial resistance in minocycline compared to tetracycline-treated acne patients. Br J Dermatol. 1990;122:233–44.
10. Eady EA, Jones CE, Gardner KJ, et al. Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline but sensitive to minocycline. Br J Dermatol. 1993; 128:556–60.
11. Garner SE, Eady EA, Popescu C, et al. Minocycline for acne vulgaris: effi cacy and safety. Coch Data Syst Rev. 2003; Issue 1: CD002086.
12. McManus P, Iheanacho I. Don’t use minocycline as fi rst line oral antibiotic in acne. BMJ. 2007;334:154.
13. Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003;139:459–64.
14. Stewart DM, Torok HM, Weiss JS, et al. Dose-ranging effi cacy of new once-daily extended- release minocycline for acne vulgaris. Cutis. 2006;78:11–20.
15. Fleischer Jr AB, Dinehart S, Stough D, et al. Safety and effi cacy of a new extended-release formulation of minocycline for acne vulgaris. Cutis. 2006;78:21–31.
16. Sturkenboom MC, Meier CR, Jick H, Striker BH. Minocycline and lupus-like syndrome in acne patients. Arch Intern Med. 1999;159:493–7.
17. Fanelli M, Kupperman E, Lautenbach E, Edelstein PH, Margolis DJ. Antibiotics, acne, and staphylococcus aureus colonization. Arch Dermatol. 2011;147:917–21.
18. Bhambri S, Del Rosso JQ, Desai A. Oral trimethoprim/sulfamethoxazole in the treatment of acne vulgaris. Cutis. 2007;79(6):430–4.
19. Amnesteem ® (Isotretinoin Capsules USP) [package insert]. Morgantown, WV: Mylan Pharmaceuticals, Inc. 2010.
20. Strauss JS, Rapini RP, Shalita AR, et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol. 1984;10:490–6.
21. Ellis CN, Krach KJ. Uses and complications of isotretinoin therapy. J Am Acad Dermatol. 2001;45(5):S150–7.
22. White GM, Chen W, Yao J, Wolde-Tsadik G. Recurrence rates after the fi rst course of isotretinoin. Arch Dermatol. 1998;134:376–8.
23. Azoulay L, Oraichi D, Bérard A. Isotretinoin therapy and the incidence of acne relapse: a nested case-control study. Br J Dermatol. 2007;157(6):1240–8.
24. Bershad S, Rubinstein A, Paterniti JR, et al. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med. 1985;313:981–5.
25. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med. 1985; 313:837–41.
26. Adams J, Lammer EJ. Neurobehavioral teratology of isotretinoin. Reprod Toxicol. 1993; 7:175–7.
27. Margolis DJ, Attie M, Leyden JJ. Effects of isotretinoin on bone mineralization during routine therapy with isotretinoin therapy for acne vulgaris. Arch Dermatol. 1996;132:769–74.
28. Reddy D, Siegel CA, Sands BE, et al. Possible association between isotretinoin and infl ammatory bowel disease. Am J Gastroenterol. 2006;101:1569–73.
29. Azoulay L, Blais L, Koren G, et al. Isotretinoin and the risk of depression in patients with acne vulgaris: a case-crossover study. J Clin Psychiatry. 2008;69:526–32.
30. Crockett SD, Gulati A, Sandler RS, et al. A causal association between isotretinoin and infl ammatory bowel disease has yet to be established. Am J Gastroenterol. 2009;104: 2387–93.
31. Bigby M. Does isotretinoin increase the risk of depression? Arch Dermatol. 2008;144: 1197–9.
32. Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg. 2007;26:210–20.
33. Chia CY, Lane W, Chibnall J, et al. Isotretinoin therapy and mood changes in adolescents with moderate to severe acne: a cohort study. Arch Dermatol. 2005;141:557–60.
34. Lolis MS, Bowe WP, Shalita AR. Acne and systemic disease. Med Clin North Am. 2009; 93:1161–81.
35. Kelekci KH, Kelekci S, Incki K, et al. Ovarian morphology and prevalence of polycystic ovary syndrome in reproductive aged women with or without mild acne. Int J Dermatol. 2010; 49:775–9.
36. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA. 2004;292:726–35.
37. Junkins-Hopkins JM. Hormone therapy for acne. J Am Acad Dermatol. 2010;62(3):486–8.
38. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Coch Data Syst Rev. 2009; Issue 3: CD004425.
39. Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis. 2004;74:123–30.
40. Yaz ® (Drospirenone/Ethinyl estradiol) [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals, Inc.: 2011.
41. Castelli WP. Cardiovascular disease: pathogenesis, epidemiology, and risk among users of oral contraceptives who smoke. Am J Obstet Gynecol. 1999;180:S349–56.
42. Helms SE, Bredle DL, Zajic J, Jatjoura D, Brodell RT, Krishnarao I. Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol. 1997;36:705–10.
43. Dickinson BD, Altman RD, Nielsen NH, Sterling ML, Council on Scientific Affairs, American Medical Association. Interactions between oral contraceptives and antibiotics. Obstet Gynecol. 2001;98:853–60.
44. Berenson AB, Odom SD, Breitkopf CR, Rahman M. Physiologic and psychologic symptoms associated with use of injectable contraception and 20 microg oral contraceptive pills. Am J Obstet Gynecol. 2008;199:351.e1–e12.
45. Goodfellow A, Alaghband-Zadeh J, Carter G, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol. 1984;111:209–14.
46. Brown J, Farquhar C, Lee O, et al. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Coch Data Syst Rev. 2009; Issue 2:CD000194.
47. Saint-Jean M, Ballanger F, Nguyen J, Khammari A, Dréno B. Importance of spironolactone in the treatment of acne in adult women. J Eur Acad Dermatol Venereol. 2010;25:1480–1. doi: 10.1111/j.1468-3083.2010.03926.x.
48. Muhlemann MF, Carter GD, Cream JJ, Wise P. Oral spironolactone: an effective treatment for acne vulgaris in women. Br J Dermatol. 1986;115:227–32.
49. Burke BM, Cunliffe WJ. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br J Dermatol. 1985;112:124–5.
50. Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol. 2000;43:498–502.
51. Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as fi rst line therapy? Facts and controversies. Clin Dermatol. 2010;28:17–23.
52. Van Wayjen R, van den Ende A. Experience in the long term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: effi cacy, metabolic, and endocrine effects. Exp Clin Endocrinol Diabetes. 1995;103:241–51.
53. Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol. 2004;22:419–28.